Preparation method of high-purity cloxacillin sodium crystal

By using the evaporation-dissolution coupled crystallization method during the preparation of chloroxacillin sodium, the problems of uneven particle size and low purity of the crystals of chloroxacillin sodium in the prior art are solved, and high purity and good powder performance are achieved. Meets the Chinese Pharmacopoeia standards.

CN119019419AActive Publication Date: 2024-11-26TIANJIN UNIV +1

Patent Information

Application Number
CN202411117177.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-26
Estimated Expiration
2044-08-15

AI Technical Summary

Technical Problem

During the preparation process of existing chloroxacillin sodium, there are problems such as uneven crystal particle size, easy to coalescence, serious impurities storage, irregular appearance and morphology, resulting in low product purity and serious solvent residues, making it difficult to meet the strict standards of the Chinese Pharmacopoeia.

Method used

Starting from 6-aminopenicillin alkanoic acid, reacting, acidifying, extracting, and salting with orthochloric acid chloride, and finally preparing high-purity sodium chlorozoicillin crystals through evaporation-dissolution coupled crystallization method, controlling the crystal growth process and improving the product particle size uniformity and purity.

Benefits of technology

The product has achieved high purity, stability and good powder performance. The crystal particle size is greater than 200μm, the rest angle is less than 26.2°, it is not easy to contain impurities, the solvent residue is low, and the purity reaches 97.6%, which meets the Chinese Pharmacopoeia standards.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019419A_ABST
    Figure CN119019419A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of a high-purity cloxacillin sodium crystal. The method comprises the following steps: reacting 6-aminopenicillanic acid (6-APA) serving as an initial raw material with o-chloroacyl chloride, acidizing, extracting and separating to obtain an acid solution for salt forming reaction, adding a proper salt forming agent into the acid solution for salt forming reaction, and performing salt forming reaction, thereby obtaining the product. Finally, a cloxacillin sodium crystal product with excellent powder performance and high purity is obtained by means of evaporation-coupling crystallization. The preparation method particularly emphasizes the simplicity and convenience of operation, the high purity of the product (the purity calculated according to an anhydrous substance is as high as 97.6%) and the excellent powder performance (the particle size is greater than 200 microns, and the angle of repose is less than 26.5 degrees), and emphasizes the optimization of the product stability, so that the high quality and reliability of the product are ensured.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicine and chemical industry, and particularly relates to a method for preparing high-purity cloxacillin sodium crystals with good powder properties. Background Art

[0002] Cloxacillin Sodium, also known as o-cloxacillin sodium, has a chemical name of: 6-[3-(2-chlorophenyl)-5-methyl-4-isoxazolecarboxamido] penicillin sodium, chemical formula C 19 H 17 ClN3O5SNa·H2O, with a molar mass of 475.88 and a structural formula as shown below, is a white or off-white crystalline powder with hygroscopic properties. It is mainly used clinically to treat sepsis, endocarditis, respiratory tract infections, and skin and soft tissue infections caused by penicillinase-resistant Staphylococcus aureus.

[0003]

[0004] In the current pharmaceutical industry environment, one of the main challenges encountered by domestic cloxacillin sodium in the preparation process is that the clarity and purity of the final product fail to meet the strict standards of the Chinese Pharmacopoeia for the drug, and the poor crystal fluidity leads to difficulties in packaging. The core of this problem is that the cloxacillin sodium products produced by traditional processes have shortcomings such as small crystal size, unevenness, easy agglomeration, serious impurity inclusion, irregular appearance, and incomplete crystal habits. These factors together lead to quality problems such as low product purity, serious solvent residue problems, and yellow or yellow-green products.

[0005] The conventional production method of cloxacillin sodium involves dissolving o-chloroacyl chloride and 6-aminopenicillanic acid (6-APA) in acetone, mixing and performing an acylation reaction. After the reaction is completed, it needs to be further acidified and butyl acetate is used as an extractant to obtain a cloxacillin acid butyl ester solution. Subsequently, a butyl acetate solution containing sodium salt is added to this solution to promote the crystallization of cloxacillin sodium. After the crystallization is completed, the final product is obtained by washing and vacuum drying. However, the production process is affected by multiple factors such as reaction rate, diffusion rate, reaction heat, phase change heat, etc., resulting in a series of technical problems, including low liquid content, long filtration time, difficult drying, small and incomplete crystals, uneven particle size, large batch differences, low yield, visible foreign matter exceeding the standard, and excessive solvent residues, etc. These problems further increase the production and post-processing costs, so it is urgent to develop a new high-purity cloxacillin sodium production technology.

[0006] Domestic and foreign research on the crystallization process of cloxacillin sodium (Li Zhonghua, "Synthesis of Cloxacillin Sodium", 2002) pointed out that after mixing the butyl acetate solution of cloxacillin acid with methanol, sodium isooctanoate and butyl acetate, the crystallization can be promoted by heating and natural cooling. Although this method can achieve a certain yield and purity, it has obvious defects, such as the accelerated degradation rate of cloxacillin sodium caused by excessively high reaction temperature, improper control of sodium isooctanoate dosage, and the uneven crystal size and product agglomeration caused by the natural precipitation crystallization method. These factors not only affect the product quality, but also limit the application efficiency and economy of the process.

[0007] In response to these challenges, future research and process improvements need to focus on improving crystal quality and morphology, reducing solvent residues, and increasing the overall purity and yield of the product, and further achieve higher industrial application standards and economic benefits by developing new production technologies for cloxacillin sodium. Summary of the invention

[0008] The invention discloses a novel evaporation-solution coupled crystallization method for generating high-purity cloxacillin sodium crystals by starting from 6-aminopenicillanic acid (6-APA), reacting with o-chloroacyl chloride, acidifying, extracting, forming salts, and finally crystallizing. The method is simple to operate, has high product purity, and good stability. The product crystal habit is in the form of relatively large and complete flakes, with a particle size greater than 200 μm and a repose angle less than 26.2°. It is not easy to contain impurities, has low solvent residue, has a high conversion rate based on 6-APA, a high molar yield, and is easy for industrial production.

[0009] The preparation method of cloxacillin sodium disclosed by the present invention has the following characteristic steps:

[0010] Step 1: Add 6-APA and a certain proportion of solvent I and solvent II solution into the crystallizer, control the temperature in the crystallizer, adjust the pH value of the system to a certain pH value, and stir to dissolve it to form solution A;

[0011] Dissolve o-chloroacyl chloride in solvent II to prepare solution B;

[0012] Solution B is added to the crystallizer at a certain flow rate to react with solution A for 0.5 to 2 hours;

[0013] Step 2: After the reaction is completed, add solvent III to the crystallizer for extraction, adjust the system to a certain pH value, stand for phase separation, and take the upper organic phase in the crystallizer for standby use;

[0014] Step 3: controlling the temperature in the crystallizer, and adding a certain amount of a solution prepared by a salt-forming agent and solvent IV into the crystallizer at a certain flow rate to perform a salt-forming reaction;

[0015] Step 4: Add a certain amount of solvent V to the crystallizer, grow the crystals for a period of time after the crystals are produced, and continue to add a certain amount of the solvent;

[0016] Step 5: Start the vacuum pump and control the vacuum degree in the crystallizer to a certain value. When the solid content in the crystallizer reaches a certain proportion, stop the vacuum operation and continue to grow crystals for a period of time;

[0017] Step 6: perform solid-liquid separation, wash the filter cake, and place the obtained crystals in a drying oven for drying to obtain the final product.

[0018] Preferably, any of the above items is that the solvent I is one of methanol, water, ethanol and dichloromethane, and the solvent II is one of acetone, acetonitrile, isopropanol and dichloromethane.

[0019] Preferably, in any one of the above items, the temperature in step 1 is maintained at 0-10°C.

[0020] Preferably, in any of the above items, the mass ratio of solvent I to solvent II in step 1 is 1:1 to 1:1.5.

[0021] Preferably, in any of the above items, the mass ratio of 6-APA to the mixed solvent (solvent I and solvent II) in step 1 is 1:5 to 1:15.

[0022] Preferably, in any of the above items, the pH value in step 1 is controlled in the range of 4.0 to 9.0.

[0023] Any of the above is preferably that the inorganic base or inorganic acid used to adjust the pH in step 1 is one of sodium hydroxide, sodium carbonate, sodium bicarbonate, and dilute sulfuric acid or hydrochloric acid.

[0024] Any of the above is preferably that the solvent II used in step 1 is one of acetone, acetonitrile, isopropanol and dichloromethane.

[0025] Preferably, in any of the above items, the mass ratio of 6-APA to o-chloroacyl chloride used in step 1 is 1:1 to 1:1.3.

[0026] Any one of the above is preferably that the mass ratio of o-chloroacyl chloride used in step 1 to solvent II is 1:2 to 1:5.

[0027] Preferably, in any of the above items, the flow rate of solution B in step 1 is 2-6 mL / min.

[0028] Preferably, in any of the above items, the solvent III in step 2 is an extractant, specifically one of ethyl acetate, butyl acetate, isopropyl acetate and petroleum ether.

[0029] Preferably, in any of the above items, the mass ratio of solvent III to solvent I in step 2 is 1.5:1 to 2.4:1.

[0030] Preferably, in any of the above items, the pH value in step 2 is controlled in the range of 4.0 to 9.0.

[0031] Any of the above items is preferably that the inorganic base or inorganic acid used to adjust the pH in step 2 is one of sodium hydroxide, sodium carbonate, sodium bicarbonate, and dilute sulfuric acid or hydrochloric acid.

[0032] Any of the above is preferably that in step 3, the temperature in the crystallizer is controlled to be 20-30°C.

[0033] Preferably, in any of the above items, the salt-forming agent in step 3 is one of sodium bicarbonate, sodium ethoxide and sodium isooctanoate, and the molar ratio of the salt-forming agent to 6-APA is 1:1 to 1.2:1.

[0034] Any of the above is preferably that the solvent IV used in step 3 is one of methanol, acetone, ethyl acetate and butyl acetate.

[0035] Preferably, in any of the above items, the ratio of solvent IV to salt-forming agent in step 3 is 1:1 to 2:1.

[0036] Preferably, in any of the above items, the flow rate of the salt-forming solution in step 3 is 2-6 mL / min.

[0037] Preferably, in any of the above items, the salt-forming reaction time in step 3 is 0.5 to 1 h.

[0038] Any of the above items is preferably that the solvent V in step 4 is one of ethyl acetate, butyl acetate, isopropyl acetate and petroleum ether.

[0039] Preferably, in any of the above items, the mass ratio of the total amount of solvent V to solvent III in step 4 is 1.5:1 to 3:1.

[0040] Preferably, in any of the above items, the flow rate of the solvent V in step 4 is controlled at 0.1 to 10 mL / min.

[0041] Preferably, in any one of the above items, the crystal growing time in step 4 is 0.5 to 2 hours.

[0042] Any of the above is preferably that the temperature in the crystallizer in step 5 is controlled to be 20-30°C.

[0043] Any of the above items is preferably that the vacuum degree in the crystallizer in step 5 is controlled to be -0.05 to -0.09 MPa.

[0044] Preferably, in any of the above items, the solvent evaporation rate in the crystallizer in step 5 is 5 to 10 mL / h (based on 10 g of 6-APA).

[0045] Preferably, in any of the above items, the evaporation and crystallization operation is stopped when the final solid content in step 5 reaches 15% to 30% (V / V).

[0046] Preferably, in any one of the above items, the crystal growing time in step 5 is 0.5 to 1 hour.

[0047] Preferably, in any of the above items, the detergent in step 6 is one of acetone, acetonitrile and ethanol.

[0048] Preferably, in any of the above items, the drying method in step 6 is forced air drying, the drying temperature is 40 to 50° C., and the drying time is 8 to 16 hours.

[0049] Advantages and beneficial effects of the present invention

[0050] (1) The present invention controls crystal growth by coupling the crystallization process, and the resulting product has uniform particle size, a complete flake shape, and is quickly filtered.

[0051] (2) The product prepared by the present invention has excellent powder performance, the crystal product has a large particle size, the particle size is greater than 200 μm, the angle of repose is less than 26.5°, and the flowability is good.

[0052] (3) The method of the present invention has good process controllability, short production cycle, small batch difference, and a single-pass molar yield of more than 80%.

[0053] (4) The product obtained by this method has low solvent residue and total impurities as low as 0.3%, the purity of cloxacillin sodium is as high as 97.6% (anhydrous basis), and the stability is excellent.

[0054] (5) The product prepared by the present invention is clear after dissolution, and the pH value is 5.8 to 6.1, which is in line with the provisions of the Chinese Pharmacopoeia. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1a Microscope image of the cloxacillin sodium product prepared in Example 1 of the present invention.

[0056] Figure 1b TEM image of the cloxacillin sodium product prepared in Example 1 of the present invention.

[0057] Figure 2 XRD patterns of the cloxacillin sodium products prepared in Examples 1 to 7 of the present invention.

[0058] Figure 3 TG / DSC graph of the cloxacillin sodium product prepared in Example 1 of the present invention.

[0059] Figure 4 Raman spectra of the cloxacillin sodium products prepared in Examples 1 to 7 of the present invention. DETAILED DESCRIPTION

[0060] The present invention is described more clearly and completely through the following examples, but the examples described are only part of the embodiments of the present invention, not all of them. The embodiments are to help understand the present invention and should not be used to limit the scope of protection of the present invention.

[0061] Embodiment 1:

[0062] A method for preparing high-purity cloxacillin sodium crystals, comprising the following steps:

[0063] Step 1: Dissolve 10g of 6-APA in a mixed solution of 25mL water + 32mL acetone at 5°C, and use 2-3M sodium carbonate solution to adjust the solution pH to about 8.2 to obtain a 6-APA solution (denoted as A). Dissolve 12g of o-chloroacyl chloride in 40mL acetone at room temperature to obtain an o-chloroacyl chloride solution (denoted as B). Control the crystallizer temperature to 5°C, add solution B to the crystallizer at a rate of 4mL / min, and perform condensation reaction with solution A for 1h.

[0064] Step 2: Add 60 mL of ethyl acetate to the crystallizer for extraction and stir for 20 min. Use dilute sulfuric acid solution to adjust the solution pH to 4.0, let stand for 30 min, and take the upper organic phase to the crystallizer.

[0065] Step 3: At 25°C, dissolve 10 g of sodium isooctanoate in 10 mL of ethyl acetate solution (referred to as solution C), start stirring, and add solution C to the crystallizer at a flow rate of 2 mL / min to carry out salt-forming reaction for 0.5 h.

[0066] Step 4: Add 110 mL of ethyl acetate dropwise into the crystallizer at a flow rate of 3 mL / min. After the crystals appear, they need to be grown for 0.5 h. Then, continue to add the remaining ethyl acetate at a flow rate of 0.2 mL / min, and then grow the crystals for 1 h.

[0067] Step 5: Control the temperature in the crystallizer to 25°C, and carry out reduced pressure evaporation crystallization process at -0.05 MPa. Evaporate 37 mL of solution at a uniform rate within 5 hours. When the solid content in the crystallizer is about 25% (V / V), stop the reduced pressure evaporation and continue to grow the crystal at this temperature and stirring rate for 0.5 hours.

[0068] Step 6: Perform solid-liquid separation and wash the sample with acetone. Place the washed solid sample in a forced air drying oven, set the oven temperature to 45°C, and dry for 10 hours to obtain the cloxacillin sodium product.

[0069] The final product is white flaky crystals, and the X-ray powder diffraction spectrum is as follows: Figure 2 The molar yield is 80.8%, the purity is 97.0% (anhydrous), the aqueous solution is colorless, clear and transparent, the acidity is 5.98, the product particle size is about 230 μm, and the angle of repose is 22.4°.

[0070] Embodiment 2:

[0071] A method for preparing high-purity cloxacillin sodium crystals, comprising the following steps:

[0072] Step 1: Dissolve 10g of 6-APA in a mixed solution of 40mL methanol + 60mL acetonitrile at 5°C, and use 2-3M dilute sulfuric acid solution to adjust the solution pH to about 4.0 to obtain a 6-APA solution (denoted as A). Dissolve 13g of o-chloroacyl chloride in 65mL acetonitrile at room temperature to obtain an o-chloroacyl chloride solution (denoted as B). Control the crystallizer temperature to 5°C, add solution B to the crystallizer at a rate of 6mL / min, and perform condensation reaction with solution A for 1h.

[0073] Step 2: Add 60 mL of ethyl acetate to the crystallizer for extraction and stir for 20 min. Use sodium carbonate solution to adjust the solution pH to 8.5, let stand for 30 min, and take the upper organic phase to the crystallizer.

[0074] Step 3: At 20°C, dissolve 11 g of sodium isooctanoate in 22 mL of ethyl acetate solution (referred to as solution C), start stirring, and add solution C to the crystallizer at a flow rate of 2 mL / min to carry out salt-forming reaction for 1 hour.

[0075] Step 4: Add 90 mL of ethyl acetate dropwise to the crystallizer at a flow rate of 2 mL / min. After the crystals appear, they need to be grown for 1 hour. Then, continue to add the remaining ethyl acetate at a flow rate of 0.1 mL / min, and then grow the crystals for 1 hour.

[0076] Step 5: Control the temperature in the crystallizer to 20°C, and carry out reduced pressure evaporation crystallization process at -0.06MPa. Evaporate 27mL of solution at a uniform rate within 5h. When the solid content in the crystallizer is about 21% (V / V), stop the reduced pressure evaporation and continue to grow the crystal at this temperature and stirring rate for 0.8h.

[0077] Step 6: Perform solid-liquid separation and wash the sample with acetone. Place the washed solid sample in a forced air drying oven, set the oven temperature to 40°C, and dry for 8 hours to obtain the cloxacillin sodium product.

[0078] The final product is white flaky crystals, and the X-ray powder diffraction spectrum is as follows: Figure 2The molar yield is 78.2%, the purity is 96.3% (anhydrous), the aqueous solution is colorless, clear and transparent, the acidity is 5.87, the product particle size is about 235 μm, and the angle of repose is 18.8°.

[0079] Embodiment 3:

[0080] A method for preparing high-purity cloxacillin sodium crystals, comprising the following steps:

[0081] Step 1: Dissolve 10g of 6-APA in a mixed solvent of 70mL ethanol + 80mL isopropanol at 0°C, and use 2-3M sodium bicarbonate solution to adjust the solution pH to about 9.0 to obtain a 6-APA solution (denoted as A). Dissolve 11g of o-chloroacyl chloride in 22mL isopropanol at room temperature to obtain an o-chloroacyl chloride solution (denoted as B). Control the crystallizer temperature to 0°C, add solution B to the crystallizer at a rate of 2mL / min, and perform condensation reaction with solution A for 1h.

[0082] Step 2: Add 140 mL of butyl acetate to the crystallizer for extraction and stir for 20 min. Use hydrochloric acid solution to adjust the solution pH to 4.0, let stand for 30 min, and take the upper organic phase to the crystallizer.

[0083] Step 3: At 30°C, 12 g of sodium ethoxide was dissolved in 20 mL of butyl acetate solution (referred to as solution C), stirring was started, and solution C was added to the crystallizer at a flow rate of 4 mL / min to carry out salt-forming reaction for 0.8 h.

[0084] Step 4: Add 300 mL of butyl acetate dropwise to the crystallizer at a flow rate of 10 mL / min. After the crystals are produced, they need to be grown for 2 hours. Then, the remaining butyl acetate is added at a flow rate of 0.5 mL / min. Then, the temperature in the crystallizer is maintained at 30°C and the crystals are grown for 0.5 hours.

[0085] Step 5: Control the temperature in the crystallizer to 30°C, and carry out reduced pressure evaporation crystallization process at -0.06MPa. Evaporate 50mL of solution at a uniform rate within 5h. When the solid content in the crystallizer is about 28% (V / V), stop the reduced pressure evaporation and continue to grow the crystal at this temperature and stirring rate for 1h.

[0086] Step 6: Perform solid-liquid separation and wash the sample with acetonitrile. Place the washed solid sample in a forced air drying oven, set the oven temperature to 45°C, and dry for 16 hours to obtain the cloxacillin sodium product.

[0087] The final product is white flaky crystals, and the X-ray powder diffraction spectrum is as follows: Figure 2The molar yield is 81.1%, the purity is 96.7% (anhydrous), the aqueous solution is colorless, clear and transparent, the acidity is 6.07, the product particle size is about 260 μm, and the angle of repose is 15.6°.

[0088] Embodiment 4:

[0089] A method for preparing high-purity cloxacillin sodium crystals, comprising the following steps:

[0090] Step 1: Dissolve 10g of 6-APA in a mixed solution of 22mL of dichloromethane + 28mL of acetone at 3°C, and use 2-3M sodium hydroxide solution to adjust the solution pH to about 7.5 to obtain a 6-APA solution (denoted as A). Dissolve 10g of o-chloroacyl chloride in 40mL of dichloromethane at room temperature to obtain an o-chloroacyl chloride solution (denoted as B). Control the crystallizer temperature to 3°C, add solution B to the crystallizer at a rate of 3mL / min, and perform condensation reaction with solution A for 1h.

[0091] Step 2: Add 40 mL of isopropyl acetate to the crystallizer for extraction and stir for 20 min. Use dilute sulfuric acid solution to adjust the solution pH to 6.0, let stand for 30 min, and take the upper organic phase to the crystallizer.

[0092] Step 3: At 28°C, 10 g of sodium bicarbonate was dissolved in 15 mL of methanol solution (referred to as solution C), stirring was started, and solution C was added to the crystallizer at a flow rate of 3 mL / min to carry out salt-forming reaction for 1 hour.

[0093] Step 4: 120 mL of isopropyl acetate was added dropwise to the crystallizer at a flow rate of 8 mL / min. After the crystals appeared, they needed to be grown for 1 hour, and then the remaining ethyl acetate was added at a flow rate of 0.4 mL / min. The temperature in the crystallizer was maintained at 28°C and the crystals were grown for 2 hours.

[0094] Step 5: Control the temperature in the crystallizer to 28°C, and carry out reduced pressure evaporation crystallization process at -0.09 MPa. Evaporate 47 mL of solution at a uniform rate within 5 hours. When the solid content in the crystallizer is about 30% (V / V), stop the reduced pressure evaporation and continue to grow the crystal at this temperature and stirring rate for 0.6 hours.

[0095] Solid-liquid separation was performed, and the sample was washed with ethanol. The washed solid sample was placed in a forced air drying oven, the temperature in the oven was set to 50°C, and dried for 8 hours to obtain the cloxacillin sodium product.

[0096] Step 6: The final product is flaky white crystals, and the X-ray powder diffraction spectrum is as follows Figure 2The molar yield is 80.1%, the purity is 96.1% (anhydrous), the aqueous solution is colorless, clear and transparent, the acidity is 5.78, the product particle size is about 290 μm, and the angle of repose is 15.3°.

[0097] Embodiment 5:

[0098] A method for preparing high-purity cloxacillin sodium crystals, comprising the following steps:

[0099] Step 1: At 8°C, dissolve 10g of 6-APA in a mixed solution of 50mL of dichloromethane + 50mL of isopropanol, and use 2-3M hydrochloric acid solution to adjust the solution pH to about 4.5 to obtain a 6-APA solution (denoted as A). Dissolve 12g of o-chloroacyl chloride in 50mL of isopropanol at room temperature to obtain an o-chloroacyl chloride solution (denoted as B). Control the crystallizer temperature to 8°C, add solution B to the crystallizer at a rate of 5mL / min, and perform condensation reaction with solution A for 1h.

[0100] Step 2: Add 90 mL of petroleum ether to the crystallizer for extraction and stir for 20 min. Use sodium bicarbonate solution to adjust the solution pH to 9.0, let stand for 30 min, and take the upper organic phase to the crystallizer.

[0101] Step 3: At 22°C, dissolve 11 g of sodium isooctanoate in 10 mL of acetone solution (referred to as solution C), start stirring, and add solution C to the crystallizer at a flow rate of 2 mL / min to carry out salt-forming reaction for 0.5 h.

[0102] Step 4: Add 135 mL of petroleum ether to the crystallizer at a flow rate of 6 mL / min. After the crystals appear, they need to be grown for 0.5 h. Then, the remaining petroleum ether is added at a flow rate of 0.3 mL / min. Then, the temperature in the crystallizer is maintained at 22°C and the crystals are grown for 1 h.

[0103] Step 5: Control the temperature in the crystallizer to 22°C, and carry out reduced pressure evaporation crystallization process at -0.07 MPa. Evaporate 32 mL of solution at a uniform rate within 5 hours. When the solid content in the crystallizer is about 18% (V / V), stop the reduced pressure evaporation and continue to grow the crystal at this temperature and stirring rate for 1 hour.

[0104] Step 6: Perform solid-liquid separation and wash the sample with ethanol. Place the washed solid sample in a forced air drying oven, set the oven temperature to 45°C, and dry for 16 hours to obtain the cloxacillin sodium product.

[0105] The final product is flaky white crystals, and the X-ray powder diffraction spectrum is as follows Figure 2The molar yield is 79.2%, the purity is 96.2% (anhydrous), the aqueous solution is colorless, clear and transparent, the acidity is 5.84, the product particle size is about 205 μm, and the angle of repose is 26.3°.

[0106] Embodiment 6:

[0107] A method for preparing high-purity cloxacillin sodium crystals, comprising the following steps:

[0108] Step 1: At 5°C, dissolve 10g of 6-APA in a mixed solution of 50mL ethanol + 72mL dichloromethane, and use 2-3M sodium carbonate solution to adjust the solution pH to about 8.0 to obtain a 6-APA solution (denoted as A). At room temperature, dissolve 11.5g of o-chloroacyl chloride in 40mL dichloromethane to obtain an o-chloroacyl chloride solution (denoted as B). Control the crystallizer temperature to 5°C, add solution B to the crystallizer at a rate of 4mL / min, and perform condensation reaction with solution A for 1h.

[0109] Step 2: Add 100 mL of butyl acetate to the crystallizer for extraction and stir for 20 min. Use dilute sulfuric acid solution to adjust the solution pH to 6.5, let stand for 30 min, and take the upper organic phase to the crystallizer.

[0110] Step 3: At 20°C, 11.2 g of sodium ethoxide was dissolved in 20 mL of butyl acetate solution (referred to as solution C), stirring was started, and solution C was added into the reversing crystallizer at a flow rate of 6 mL / min to carry out salt-forming reaction for 1 hour.

[0111] Step 4: Add 250 mL of butyl acetate dropwise to the crystallizer at a flow rate of 10 mL / min. After the crystals are formed, they need to be grown for 1.5 hours. Then, the remaining butyl acetate is added at a flow rate of 0.5 mL / min. Then, the temperature in the crystallizer is maintained at 20°C and the crystals are grown for 1.5 hours.

[0112] Step 5: Control the temperature in the crystallizer to 20°C, and carry out the reduced pressure evaporation crystallization process at -0.09 MPa. Evaporate 31 mL of the solution at a uniform rate within 5 hours. When the solid content in the crystallizer is about 18% (V / V), stop the reduced pressure evaporation and continue to grow the crystal at this temperature and stirring rate for 0.5 hours.

[0113] Step 6: Perform solid-liquid separation and wash the sample with acetonitrile. Place the washed solid sample in a forced air drying oven, set the oven temperature to 45°C, and dry for 12 hours to obtain the cloxacillin sodium product.

[0114] The final product is flaky white crystals, and the X-ray powder diffraction spectrum is as follows Figure 2The molar yield is 78.8%, the purity is 95.9% (anhydrous), the aqueous solution is colorless, clear and transparent, the acidity is 5.88, the product particle size is about 240 μm, and the angle of repose is 19.4°.

[0115] Embodiment 7:

[0116] A method for preparing high-purity cloxacillin sodium crystals, comprising the following steps:

[0117] Step 1: At 10°C, dissolve 10g of 6-APA in a mixed solution of 36mL water + 50mL acetonitrile, and use 2-3M dilute sulfuric acid solution to adjust the solution pH to about 4.8 to obtain a 6-APA solution (denoted as A). At room temperature, dissolve 12.5g of o-chloroacyl chloride in 60mL acetonitrile to obtain an o-chloroacyl chloride solution (denoted as B). Control the crystallizer temperature to 10°C, add solution B to the crystallizer at a rate of 6mL / min, and perform condensation reaction with solution A for 1h.

[0118] Step 2: Add 80 mL of isopropyl acetate to the crystallizer for extraction and stir for 20 min. Use sodium hydroxide solution to adjust the solution pH to 8.5, let stand for 30 min, and take the upper organic phase to the crystallizer.

[0119] Step 3: At 25°C, 12 g of sodium isooctanoate was dissolved in 10 mL of acetone solution (referred to as solution C), stirring was started, and solution C was added to the crystallizer at a flow rate of 3 mL / min to carry out salt-forming reaction for 0.6 h.

[0120] Step 4: 120 mL of isopropyl acetate was added dropwise to the crystallizer at a flow rate of 7 mL / min. After the crystals were formed, they were grown for 0.5 h, and then the remaining isopropyl acetate was added at a flow rate of 0.8 mL / min. The temperature in the crystallizer was then maintained at 25°C and the crystals were grown for 1 h.

[0121] Step 5: Control the temperature in the crystallizer to 25°C, and carry out the reduced pressure evaporation crystallization process at -0.05 MPa. Evaporate 50 mL of the solution at a uniform rate within 5 hours. When the solid content in the crystallizer is about 22% (V / V), stop the reduced pressure evaporation and continue to grow the crystal at this temperature and stirring rate for 0.5 hours.

[0122] Step 6: Perform solid-liquid separation and wash the sample with acetonitrile. Place the washed solid sample in a forced air drying oven, set the oven temperature to 50°C, and dry for 8 hours to obtain the cloxacillin sodium product.

[0123] The final product is flaky white crystals, and the X-ray powder diffraction spectrum is as follows Figure 2The molar yield is 81.7%, the purity is 96.5% (anhydrous), the aqueous solution is colorless, clear and transparent, the acidity is 5.95, the product particle size is about 320 μm, and the angle of repose is 13.8°.

[0124] Comparative Example 1:

[0125] The difference from Example 1 is that step 5 is omitted.

[0126] The final product is in the form of white powder, with a molar yield of 54.2% and a purity of 94.1% (on anhydrous basis). The aqueous solution is colorless, clear and transparent, with an acidity of 5.61. The product particle size is about 75 μm and the angle of repose is 39.1°.

[0127] Comparative Example 2:

[0128] The difference from Example 1 is that the synthesis method of cloxacillin sodium is different. Cloxacillin sodium is synthesized by a method in which cloxacillin sodium is directly reacted with sodium isooctanoate and crystallized after acylation in a mixed solution of methanol and butyl acetate, and the subsequent evaporation-solution coupled crystallization step is the same as that of Example 1. The specific steps are as follows:

[0129] Step 1: Dissolve 10 g of 6-APA in a mixed solution of 25 mL of methanol + 32 mL of butyl acetate at 5°C to obtain a 6-APA solution (denoted as A). Dissolve 12 g of o-chloroacyl chloride in 40 mL of butyl acetate at room temperature to obtain an o-chloroacyl chloride solution (denoted as B). Control the crystallizer temperature to 5°C, add solution B to the crystallizer at a rate of 4 mL / min, and react with solution A for 1 hour to obtain a mixed solution of methanol and butyl acetate of cloxacillin acid.

[0130] Step 2: At 25°C, dissolve 10 g of sodium isooctanoate in 10 mL of butyl acetate solution (referred to as solution C), start stirring, and add solution C into the crystallizer at a flow rate of 2 mL / min to carry out salt-forming reaction for 0.5 h to form a solid-liquid suspension of cloxacillin sodium.

[0131] Step 3: Add 110 mL of butyl acetate dropwise to the crystallizer at a flow rate of 3 mL / min. After the addition is complete, grow the crystal for 1 hour.

[0132] Step 4: Control the temperature in the crystallizer to 25°C, and carry out the reduced pressure evaporation crystallization process at -0.05 MPa. Evaporate 37 mL of the solution at a uniform rate within 5 hours. When the solid content in the crystallizer is about 25% (V / V), stop the reduced pressure evaporation and continue to grow the crystal at this temperature and stirring rate for 0.5 hours.

[0133] Step 5: Perform solid-liquid separation and wash the sample with acetone. Place the washed solid sample in a forced air drying oven, set the oven temperature to 45°C, and dry for 10 hours to obtain the cloxacillin sodium product.

[0134] The final product is in the form of yellow powder, with a molar yield of 75.8%, a purity of 91.2% (anhydrous basis), a light yellow and clear aqueous solution, an acidity of 5.37, a product particle size of about 31 μm, and a repose angle of 42.4°.

[0135] Chemical property testing

[0136] 1) The chemical stability of cloxacillin sodium prepared in Examples 1-7 and Comparative Examples 1-2 of the present invention was investigated. During storage at 30±5°C and 40±5%RH for 30 days, the color, purity and morphology of the product did not change, indicating that the crystal had good chemical stability. The investigation results are shown in Table 1.

[0137] Table 1 Chemical stability study of cloxacillin sodium of the present invention

[0138]

[0139] 2) The chemical stability of the cloxacillin sodium prepared in Examples 1-7 of the present invention and Comparative Examples 1-2, such as turbidity and acidity, was investigated. During storage for 30 days at 30±5°C and 40±5%RH, the acidity and turbidity of the product were investigated and basically did not change, indicating that the crystal had good stability. The results of the investigation are shown in Table 2.

[0140] Table 2 Stability study of turbidity and acidity of nafcillin sodium of the present invention

[0141]

[0142]

[0143] 3) The powder properties of the cloxacillin sodium crystal products prepared in Examples 1-7 and Comparative Examples 1-2 of the present invention were investigated. During storage for 30 days at 30±5°C and 40±5%RH, the angle of repose of the products was investigated and basically did not change, indicating that the crystal powder had good stability. The results of the investigation are shown in Table 3.

[0144] Table 3 Performance stability test table of nafcillin sodium powder of the present invention (±0.1°)

[0145]

[0146] The above description is only a preferred embodiment of the present invention. It should be pointed out that a person skilled in the art can make several modifications and improvements without departing from the inventive concept, which all belong to the protection scope of the present invention.

Claims

1. A method for preparing high-purity cloxacillin sodium crystals, comprising the following steps: Step 1: Add 6-APA and a solvent I and a solvent II solution with a mass ratio of 1:1 to 1:1.5 into a crystallizer, control the temperature in the crystallizer to 0 to 10°C, adjust the pH value to 4.0 to 9.0, and stir to dissolve them to prepare a solution A, wherein the solvent I is one of methanol, water, ethanol and dichloromethane, and the solvent II is one of acetone, acetonitrile, isopropanol and dichloromethane; Solvent II is used to dissolve o-chloroacyl chloride to prepare solution B; solvent II is one of acetone, acetonitrile, isopropanol and dichloromethane; solution B is added to the crystallizer at a certain flow rate, and reacts with solution A for 0.5 to 2 hours, and the mass ratio of 6-APA to o-chloroacyl chloride is 1:1 to 1:1.3; Step 2: After the reaction is completed, solvent III is added to the crystallizer for extraction, the pH value of the system is adjusted to 4.0-9.0, the phases are allowed to stand for separation, and the upper organic phase is taken from the crystallizer for standby use; solvent III is one of ethyl acetate, butyl acetate, isopropyl acetate and petroleum ether; Step 3: controlling the temperature in the crystallizer to 20-30° C., and adding a certain amount of a solution prepared by a salt-forming agent and a solvent IV to the crystallizer at a certain flow rate to perform a salt-forming reaction for 0.5-1 h; the salt-forming agent is one of sodium bicarbonate, sodium ethoxide, and sodium isooctanoate, and the molar ratio of the salt-forming agent to 6-APA is 1:1-1.2:1, and the solvent IV is one of methanol, acetone, ethyl acetate, and butyl acetate; Step 4: adding a certain amount of solvent V to the crystallizer, growing the crystals for 0.5 to 2 hours after crystallization, and continuing to add a certain amount of the solvent; the solvent V is one of ethyl acetate, butyl acetate, isopropyl acetate and petroleum ether; Step 5: Start the vacuum pump and control the vacuum degree in the crystallizer to -0.05 to -0.09 MPa. When the solid content in the crystallizer reaches 15% to 30% (V / V), stop the vacuum operation and continue growing the crystal for 0.5 to 1 hour. Step 6: perform solid-liquid separation, wash the filter cake, and place the obtained crystals in a drying oven for drying to obtain the final product.

2. The method for preparing high-purity cloxacillin sodium crystals according to claim 1, wherein the mass ratio of 6-APA to the mixed solvent in step 1 is 1:5 to 1:15, and the mixed solvent is a mixed solvent of solvent I and solvent II.

3. The method for preparing high-purity cloxacillin sodium crystals according to claim 1, wherein the mass ratio of o-chloroacyl chloride to solvent II used in step 1 is 1:2 to 1:

5.

4. The method for preparing high-purity cloxacillin sodium crystals according to claim 1, wherein the flow rate of solution B in step 1 is 2 to 6 mL / min.

5. The method for preparing high-purity cloxacillin sodium crystals according to claim 1, wherein the mass ratio of solvent III to solvent I in step 2 is 1.5:1 to 2.4:

1.

6. The method for preparing high-purity cloxacillin sodium crystals according to claim 1, wherein the ratio of solvent IV to salt-forming agent in step 3 is 1:1 to 2:

1.

7. The method for preparing high-purity cloxacillin sodium crystals according to claim 1, wherein the flow rate of the salt-forming solution in step 3 is 2 to 6 mL / min.

8. The method for preparing high-purity cloxacillin sodium crystals according to claim 1, wherein the mass ratio of the total amount of solvent V to solvent III in step 4 is 1.5:1 to 3:

1.

9. The method for preparing high-purity cloxacillin sodium crystals according to claim 1, wherein the flow rate of the solvent V in step 4 is controlled at 0.1 mL / min to 10 mL / min.

10. The method for preparing high-purity cloxacillin sodium crystals according to claim 1, wherein the solvent evaporation rate in the crystallizer in step 5 is 5 to 10 mL / h, based on 10 g of 6-APA.

Citation Information

Patent Citations

  • Method for crystallizing cloxacillin sodium

    CN102070653A

  • Crystallization preparation method of cloxacillin sodium

    CN102086213A

  • Preparation process of cloxacillin sodium

    CN111205305A

  • Method of obtaining isoxazolyl penicillines

    PL283825A1

  • Method of 6-[3-(2-chlorophenyl)-5-methylisoxazol-4-carbamino]-penicillanic acid sodium salt preparing

    RU2201419C2

Cited By

  • Coupling crystallization method for preparing dicloxacillin sodium superior product

    CN119638722A

  • Spherocrystal cloxacillin sodium and preparation method thereof

    CN121378287A